Welcome to our dedicated page for Hemostemix news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix stock.
Hemostemix Inc. reports developments tied to its autologous blood-based stem cell therapy platform, including VesCell™ (ACP-01), a patient-derived angiogenic cell therapy associated with ischemic and vascular-related conditions. Company news commonly covers clinical-study history, published results, FDA interactions, physician education, and commercialization activity in markets such as Florida, Canada, and The Bahamas.
Recurring updates also include private placements and other capital actions, leadership and scientific-advisory appointments, shareholder and governance matters, and regulatory planning for ACP-01 across indications including peripheral arterial disease, chronic limb threatening ischemia, angina, cardiomyopathies, congestive heart failure, and vascular dementia.
Hemostemix (OTCQB: HMTXF) executives Thomas Smeenk, CEO, and Peter Lacey, Chairman, are attending the 2026 Abundance360 Summit in Los Angeles to present ACP-01 (VesCell) and meet investors. The company highlights clinical literature, 498 treatments, seven clinical trials, and plans for commercialization in Florida and The Bahamas.
Hemostemix (OTCQB: HMTXF) appointed Dr. York Hsiang as Business Consultant to advance First Nations-led healthcare partnerships and operationalize ACP-01 delivery.
The role focuses on joint ventures, clinical staffing, ethical commercialization in Canada, Florida (SB 1768), and The Bahamas, plus capacity-building, governance alignment, and culturally integrated destination care.
Hemostemix (OTCQB: HMTXF) completed a pre-IND meeting with the U.S. Food and Drug Administration on January 16, 2026, receiving conditional support for its basket protocol to evaluate ACP-01 across multiple ischemic and vascular-related conditions.
The FDA indicated the approach is acceptable provided Hemostemix includes clearly defined eligibility criteria, addresses patient heterogeneity, and applies rigorous clinical and statistical design. The FDA also supported the company's plan to collect real-world evidence (RWE) from Florida, Canada, and The Bahamas consistent with FDA guidance on privacy, safety, and data integrity. Hemostemix said it will incorporate the FDA feedback in its IND submission and proceed with product comparison validation studies.
Hemostemix (OTCQB: HMTXF) closed a non-brokered private placement on Dec 31, 2025 for aggregate gross proceeds of CDN$480,000 through the issuance of 4,000,000 common shares at $0.12 per share.
Proceeds will be used for general working capital, including advancing regulatory, clinical, and commercialization initiatives for ACP-01 (VesCell), the company’s autologous angiogenic cell therapy platform. All securities are subject to a statutory hold period and the placement is subject to final acceptance by the TSX Venture Exchange.
Hemostemix (OTCQB: HMTXF) appointed Dr. David B. Alper as Multidisciplinary Physician Education Lead and added him to its Scientific Advisory Board, effective January 2026.
Dr. Alper will lead physician education and clinical engagement for VesCell (ACP-01) with three initiatives: clinical practice engagement in Florida, outreach to U.S. schools of podiatric medicine, and multidisciplinary professional forums focused on ischemic disease, patient selection, and procedural integration.
Hemostemix (OTCQB: HMTXF) announced that CEO Thomas Smeenk published a theoretical manuscript introducing the Conformal Consciousness Hypothesis (CCH), proposing a dimensionless invariant A = E/(hν) as a possible relational constant linking General Relativity, Quantum Mechanics, Cosmology, and String Theory.
The paper presents mathematical appendices on conformal transformations and discusses implications for Penrose's Conformal Cyclic Cosmology, non-computability, entanglement, and string vibrational modes. The company frames the work as evidence of the CEO's analytical approach applied to Hemostemix commercialization of VesCell (ACP-01) in markets including Florida, The Bahamas, and Canada. The manuscript is available at ConformalConsciousness.com.
Hemostemix (OTCQB: HMTXF) granted a total of 963,000 stock options on December 11, 2025, subject to regulatory approval.
Of the grant, 663,000 options vest immediately and 330,000 vest 50% on December 11, 2025 and 50% on December 11, 2026. All options carry an exercise price of $0.09 and expire on December 11, 2030. After issuance Hemostemix has 19,124,694 options issued and outstanding. The grant included 663,000 options to directors and officers and relied on specified exemptions under MI 61-101 for valuation and minority approval. The company noted the material change report was not filed at least 21 days prior due to timing.
Hemostemix (OTCQB: HMTXF) announced two corporate developments: the FDA scheduled a Pre-IND meeting on January 16, 2026 to review a Phase I basket clinical trial protocol for ACP-01 covering ischemia-related indications (vascular dementia, ischemic cardiomyopathy, PAD, generalized ischemia); and the company proposed a non-brokered private placement of up to $960,000 (8,000,000 common shares at $0.12), subject to TSXV approval. All securities will have a four-month hold period. Stated use of proceeds includes FDA preparations, clinical operations expansion in Florida, The Bahamas and Canada, and general working capital.
Hemostemix (OTCQB: HMTXF) appointed Shaune Harding, OStJ, RN (non-practicing) as Director of Patient Care & Clinical Operations effective December 4, 2025. Harding will oversee patient onboarding, comprehensive medical-records transfer, multi-year health-journey mapping, continuous wearable-data monitoring (e.g., Fitbit Sense 2), monthly follow-ups, and adverse-event tracking with escalation and formal reporting.
The role covers patient programs in The Bahamas, Florida, and Canada and is described as supporting long-term continuity of care, enabling patient data capture to advance regulatory approval of ACP-01/VesCell.
Hemostemix (OTCQB: HMTXF) will present at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, highlighting clinical data for its cell therapy ACP-01/VesCell in peripheral arterial disease and chronic limb-threatening ischemia (CLTI).
Key disclosed findings include published studies reporting 83% limb salvage, 0% mortality in some cohorts, and reported ulcer size reduction from a mean of 146 mm2 to 0.48 mm2 at 3 months in treated patients. The release notes ACP-01 is available in Florida under SB 1768.